C4 Therapeutics Advances Cemsidomide into Phase 2 Trial for Relapsed/Refractory Multiple Myeloma

Event summary

  • First patient dosed in Phase 2 MOMENTUM trial of cemsidomide + dexamethasone for relapsed/refractory multiple myeloma.
  • Phase 2 trial aims to enroll ~100 patients, with completion expected in Q1 2027.
  • Phase 1b trial of cemsidomide + elranatamab set to initiate in Q2 2026.
  • Cemsidomide is an oral IKZF1/3 degrader with a differentiated safety profile.

The big picture

C4 Therapeutics is advancing its targeted protein degradation platform with cemsidomide, aiming to establish it as a foundational therapy for multiple myeloma. The Phase 2 trial builds on promising Phase 1 data, while the upcoming Phase 1b combination study with elranatamab could expand treatment options for patients who have exhausted standard therapies. The strategy aligns with broader industry trends toward combination therapies and oral treatments in oncology.

What we're watching

Regulatory Strategy
Whether C4 Therapeutics can secure two accelerated approval paths for cemsidomide in multiple myeloma.
Clinical Efficacy
How the Phase 2 MOMENTUM trial results compare to existing IKZF1/3 degraders in terms of safety and efficacy.
Combination Therapy
The pace at which cemsidomide + elranatamab progresses through Phase 1b, given the competitive landscape in relapsed/refractory multiple myeloma.